Our company has been selected as a recipient of support for the 13th term of "FASTAR," an acceleration program run by the Organization for Small & Medium Enterprises and Regional Innovation, JAPAN.
Using this program as a springboard, we will strongly promote the development of angiogenesis therapy using ICS for severe lower limb ischemia.
We have been selected for the Direct Flight "Philadelphia Program," a program run by MEDISO (a medical venture total support project commissioned by the Ministry of Health, Labour and Welfare) to promote the overseas expansion of medical startups .
Using this program as a springboard, we will accelerate the overseas expansion of angiogenesis therapy using ICS for critical lower limb ischemia.
Updated: Jun 16
Thanks to the efforts of our medical advisor, Professor Shinya Fukumoto, our company has been certified as a venture company originating from Osaka Metropolitan University. Osaka Metropolitan University is the patent holder of ICS basic material patent No. 5725489, US 2011/0104292A1.